Rapport Therapeutics

Rapport Therapeutics is a biotechnology and healthcare startup that focuses on precision medicines tailored to the complexities of the human brain. Their approach involves targeting disease-driving neurocircuits by leveraging receptor-associated proteins (RAPs), with the aim of overcoming the limitations of existing neuromedicines. This strategy is designed to maximize efficacy while minimizing side effects. Founded in 2022, Rapport Therapeutics has garnered significant attention and support from key players in the industry, with a notable $150.00M Series B investment in August 2023. The investors in this round include Arch Venture Partners, Sofinnova Investments, Third Rock Ventures, T. Rowe Price, Fidelity, Goldman Sachs Asset Management, Logos Capital, Perceptive Advisors, Johnson & Johnson Innovation – JJDC, Surveyor Capital. The company's leadership team has a proven track record in neuroscience and drug discovery, and its creation was facilitated through a partnership between Third Rock Ventures and Johnson & Johnson Innovation-JJDC, Inc. (JJDC). Operating out of San Diego, CA, and Boston, MA, Rapport Therapeutics is poised to make significant strides in revolutionizing the treatment of neurological disorders. For more information, please visit www.rapportrx.com.